Medical Technology and Evaluation Answer

Medical Technology and Evaluation Answer Of Coursera Quiz. In this post you will get Correct Quiz & Assignment Answer of Medical Technology and Evaluation

Medical Technology and Evaluation Answer

Offered By ”University of Minnesota”

Enroll Now

N.B. We attempted our best to keep this site refreshed for our clients for nothing. You can likewise contribute by refreshing new inquiries or existing inquiry answer(s). There are numerous inquiries on our site, it is difficult for us to check them consistently. It will be extraordinary on the off chance that you can assist us with updating the site. Just let us know if you find any new questions through mail or comment . We will attempt to refresh the inquiry/answer ASAP.

Week- 1

Medical Technology Assessment Environment

1.
Question 1
Which of the following is a use a potential user of medical technology evaluation results?

1 point

• Manufacturers.
• Insurers.
• Health care providers.
• All of the above.

2.
Question 2
True or False: A medical technology evaluation is just a pricing project.

1 point

• True
• False

3.
Question 3
How can a new technology with lower costs lead to higher health care expenditures?

1 point

• The technology will only reduce expenditures.
• The technology is effective and used by a larger population than the current technology.
• No new technologies have lower costs.
• The technology has better outcomes compared to the current technology.

4.
Question 4
What is the regulatory reason that medical technology evaluation evidence is needed?

1 point

• Only payment/reimbursement.
• Venture capitalist investments.
• Pricing.
• Marketing approval and payment/reimbursement.

5.
Question 5
Which of the FDA approval phases occurs after FDA approval?

1 point

• Phase IV
• Phase III and IV
• None
• Phase I

6.
Question 6
True or False: Once approved a new drug can only be prescribed for what it was approved to treat.

1 point

• True
• False

7.
Question 7
Approximately what percent of new medical devices require a Pre-Market Approval (PMA)?

1 point

• 0 percent
• 100 percent
• 90 percent
• 10 percent

8.
Question 8
What is the next step after a drug is approved by the FDA?

1 point

• File an NDA.
• Conduct a clinical trial.
• Get insurers to pay/reimburse.
• Design the packaging.

9.
Question 9
What aspects of medical care is covered by Medicare Part A?

1 point

• Outpatient services.
• Inpatient hospital care.
• Prescription drugs.
• Patient out-of-pocket costs.

10.
Question 10
True or False: Patients may have higher cost sharing obligations for the more expensive brand name version of a drug.

1 point

• True
• False

Week- 2

Clinical Trials and Insurance Claims Data

1. following is an example of an experimental design?

1 point

Patient survey

Case study

Observational study

Randomized controlled trial

2.
Question 2

Which
of the following is not an alternative to randomization?

1 point

A placebo treatment.

Historical controls.

Systematic alternation of treatments.

Non-randomized concurrent controls.

3.
Question 3
Who is “blinded” in a double blind trial design?

1 point

Patient and Investigator/Provider

Investigator/Provider and Statistician

Patient and Caregiver

Patient and Statistician

4.
Question 4

Which
of the following elements is included in claims data?

1 point

Diagnoses and procedure codes.

Procedure codes and prices.

Prices and patient demographics.

All of the above.

5.
Question 5

Which of the following is not a benefit of claims
data?

1 point

Includes physicians’ notes.

Large samples.

Includes all sources of care.

Diagnoses and procedures.

6.
Question 6
What are DRGs used for?

1 point

FDA approval.

Medicare inpatient billing/payment.

Measuring QALYs.

Prescription drug reimbursement.

7.
Question 7

What
population is covered by Medicare?

1 point

Ages 65 and older and disabled

The working population

Anyone

None of the above

8.
Question 8

Which
of the following is not a potential source of bias?

1 point

Currency

Reporting

Detection

Selection

9.
Question 9

Which
of the following questions can a meta-analysis answer?

1 point

What is the direction of the effect?

What is the size of the effect?

Is the effect consistent across studies?

All of the above

10.
Question 10

True or False: claims data can only be used for policy
research.

1 point

True

False

Week- 3

Peer-graded Assignment: You Are The Consultant

Download

[Attention]: – To get any assignment File you must need to click here to subscribe to YouTube and after that fill up this google form]

Week- 4

Methodological Approaches and Considerations

1.
Question 1

If
an assessment is being conducted to support the case for payment/reimbursement
who is the audience?

1 point

The Food and Drug Administration (FDA)

Physicians

Insurers or Payers

Venture capitalists

2.
Question 2

What is the denominator of the incremental cost effectiveness ratio (ICER)?

1 point

Indirect costs.

Future costs.

Benefits of the new technology.

Difference in benefits.

3.
Question 3
True or False: Only cost effective technologies ICERs can be graphed on the cost effectiveness plane.

1 point

True

False

4.
Question 4

What is Bayes’
rule used for?

1 point

Measuring quality of life (QoL).

Randomization in a clinical trial.

Incorporating new information to determine a probability of interest.

Graph an ICER.

5.
Question 5

Future values of which
of the following can be discounted to present value?

1 point

Direct medical costs.

Indirect costs.

Quality adjusted life years (QALYs).

All of the above.

6.
Question 6

The
expected value of a health outcome is calculated by multiplying the outcome measure by what?

1 point

Quality of Life (QoL).

The discount rate.

Direct costs.

The probability of the outcome.

7.
Question 7

The
results of a Monte Carlo simulation can be used to determine the what information about the results of an evaluation?

1 point

Mean and variance of the results.

The mean result.

The variance of the result.

None of the above.

8.
Question 8

True or False: A Markov model allows for modeling the progression
of disease over time.

1 point

True

False

9.
Question 9

Which
of the following is not a source of uncertainty?

1 point

Future costs.

Randomness in medical cost.

Randomness in health outcomes.

Statistical variation in results.

10.
Question 10

In
a sensitivity analysis how many variables can be tested?

1 point

Only one

None

One or more

Only two